Under the Paperwork Reduction Act of 1995, no persons are requ

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
( Not for submission under 37 CFR 1.99)

Application Number			
Filing Date			
First Named Inventor Mari		olein VAN DER VOORT	
Art Unit			
Examiner Name			
Attornov Docket Numb	or.	DUNI 031440HS	

U.S.PATENTS Remove										
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear				
	1	4678277		1987-07-07	Delhaye, et al.	all				
2 5275168 1994-01-0				1994-01-04	Reintjes, et al.	all				
3 5450125 1995-09-12 Ulich, et al.		Ulich, et al.	all							
	4	6205354	B1	2001-03-20	Gellermann, et al.	all				
	5 6424850 B1 2002-07-23 Lambert all									
If you wis	h to a	d additional U.S. Paten			ease click the Add button.		Add			
			U.S.P	ATENT APPLI	CATION PUBLICATIONS		Remove			
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date			Columns,Lines where nt Passages or Relevant s Appear			
	1		A1			all				
If you wis	h to a	d additional U.S. Publis		·	n information please click the Ad					
1	FOREIGN PATENT DOCUMENTS Remove									

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)

Foreign Document

Examiner Cite

Initial\* No Number<sup>3</sup> Country

Code2 i

Application Number		
Filing Date		
First Named Inventor Mary		olem VAN DER VOORT
Art Unit		
Examiner Name		
Attorney Docket Number		PHNI 031440US

Name of Patentee or

Date Considered

Applicant of cited

Document

Pages, Columns, Lines

where Relevant Passages or Relevant

Figures Appear

	1	WO 00/02479	wo	A1	2000-01-20	Lambert	all									
If you wis	If you wish to add additional Foreign Patent Document citation information please click the Add button Add															
			NON-PATE	NT LITE	RATURE DO	CUMENTS	Remove									
Examiner Initials*	Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the leten (book, magazine, journal, serial, symposium, estalog, etc), date, pages(s), volume-issue number(s), publisher, city andor country where published.															
	BERNDT, K.: Application of Gain-Modulated Avalanche Photodiodes in Phase-Sensitive Fluorescence Spectroscopy, 1985; Optics Communications; 56(1)30-35.															
	2	BREGNI, A., et al.; Background plasma light subtraction by delay line techniques for a Thomson scattering apparatus; [982, J. Phys. E. Sci. Instruments; 15(12)1310-1312.														
	3 EVERALL, N. et al. : Picosecond Time-Resolved Raman Spectroscopy of Solids: Capabilities and Limitations for Fluorescence Rejection and the Influence of Diffuse Reflectance; 2001; Applied Spectroscopy; 55(12)1701-1708.															
	4	WATANABE, J., et al.; i 1985; Review of Scienti				copy by a gated single-pho	oton counting method;									
If you wis	h to ar	dd additional non-paten	t literature docu	ment ci	tation informat	on please click the Add	If you wish to add additional non-patent literature document citation information please click the Add button Add									

Kind Publication

Code<sup>4</sup> Date

1 See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. 2 Enter office that issued the document, by the two-letter code (WIPO Standard ST 3). 3 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the sensi number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language translation is attached

FYAMINER SIGNATURE

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner Signature

#### 

### CERTIFICATION STATEMENT

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

## OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.59(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(c) and the statement. See 37 CFR 1.97(c) and the statement. See 37 CFR 1.97(c) and the statement. See

See attached certification statement.

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

- Fee set forth in 37 CFR 1,17 (p) has been submitted herewith.
- .7 None

#### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Douglas B. McKnight/	Date (YYYY-MM-DD)	2006-06-14
Name/Print	Douglas B. McKnight	Registration Number	50447

This collection of information is required by 37 CFR 197 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C. 122 and 37 CFR.

1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patient and Trademark Office, u.S. Operationed for Comments of the Comment of Comments of Commen

### Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is \$3 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
  - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2044 and 2046. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the state of the s
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record via flori an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.